Clinical trial · Interventional
Nilotinib Versus Imatinib in Treatment of Patients With Newly Diagnosed Chronic Myeloid Leukemia
NCT03228303CI-TRIAL-00029845unknownEarly Phase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Nilotinib vs imatinib in patients with newly diagnosed CML-CP
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chronic Myeloid Leukemia | Chronic Myeloid Leukemia, BCR-ABL1 Positive | ALIAS | 0.90 |
Interventions
Interventions (2)
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Chronic phase CML treated by nilotinib
- description
- Newly diagnosed
- interventionNames
- Drug: Nilotinib 150 MG [Tasigna]
- type
- ACTIVE_COMPARATOR
- label
- Chronic phase CML treated by imatinib
- description
- Newly diagnosed
- interventionNames
- Drug: Imatinib 400mg
Primary outcomes (4)
- measure
- Nilotinib vs imatinib in patients with newly diagnosed CML-CP: Overall survival rate in years
- timeFrame
- 3 years cutoff
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * chronic phase CML not received treatment * Pts with no heart disease * Pts with no abnormal cholesterol level Exclusion Criteria: * Any pts treated before with diff. Treatment * Pts. With past history of heart problems * Pts. With abnormal cholesterol level
References
Publications (0)
Data not yet available
No reference posted for this study.